Skip to main content
Caplight Logo









DEM BioPharma

DEM BioPharma

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://dembiopharma.com/

Last Round

Series A

Jun 23, 2022

Total Funding Raised

$70M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

DEM BioPharma is a biotechnology company that develops innovative immunotherapeutics targeting novel signals on cancer cells and macrophages to eliminate solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologycancer immunotherapydon't eat me signalsphagocytosisdrug discovery platformantibody-drug conjugateADCfunctional genomicsCRISPR screeningcheckpoint inhibitormacrophage therapypre-clinical biotechtumor immune evasionbiotech startupinnate immunity

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DEM BioPharma Comparables

Compare DEM BioPharma with similar companies based on industry and business-model similarity.

DEM BioPharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pheast Therapeutics
87%
ALX Oncology
75%
ImmuneOncia Therapeutics
74%

DEM BioPharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 23, 2022

Key People

Founding team and executive leadership

Nenad Grmusa

Chief Executive Officer

Executive Team

DEM BioPharma Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors increased 46% MoM.

  • Jul 24, 2026

    Monthly visitors increased 352% MoM.

DEM BioPharma Filings

Explore SEC and related filing metadata, where available.

DEM BioPharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DEM BioPharma's valuation, stock price, and market status.

Is DEM BioPharma a public or private company?

DEM BioPharma is a private company.

What is the current stock price of DEM BioPharma?

DEM BioPharma is a private company with no public stock price. No recent secondary market data is available.

How much is DEM BioPharma worth (valuation)?

Valuation information for DEM BioPharma is not publicly available.

Can I buy DEM BioPharma stock?

DEM BioPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DEM BioPharma's last funding round?

DEM BioPharma's most recent funding round was Series A on June 23, 2022.

Who are the main investors in DEM BioPharma?

Key investors in DEM BioPharma include Longwood Fund, Alta Partners.

Will DEM BioPharma IPO soon?

No public IPO plans have been announced for DEM BioPharma.

How can I track DEM BioPharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DEM BioPharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range20
Year Founded2022
Last FundingJun 23, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?